Chemicals & Advanced Materials Global On demand · 24-48h

Global Excipients for Effervescents Market Strategic Research Report

Global Excipients for Effervescents Market Strategic Researc…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Excipients for Effervescents Market
$4742025
6.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Acid Components, Carbonate And Bicarbonate Components, Fillers And Diluents, Binders And Disintegrants, Lubricants And Glidants, Sweeteners And Flavors

By Application: Pharmaceutical Products, Nutraceutical And Dietary Supplements, Food And Beverage Tablets, Veterinary Health Products

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Roquette, SPI Pharma, CD Formulation, Gattefosse, BENEO, JRS Pharma, Syensqo, lehvoss Pharma, Merck, Ashland, Shin-Etsu, chasesun, Anhui Sunhere Pharmaceutical Excipients Co., Ltd., HUNAN ER-KANG PHARMACEUTICAL, BASF Pharma Solutions, Jungbunzlauer, Solvay, Arm & Hammer Performance Products, Humens, Dr. Paul Lohmann

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 129 pages
Market size 2025
$474
Million USD
Forecast CAGR
6.8%
2025-2032
Forecast 2032
$751.2
Projected
Gebieden
5
Asia Pacific · Latin America · MEA · Europe · North America

Overzicht

Scope of the Report

The global Excipients for Effervescents market size is predicted to grow from US$ 474 million in 2025 to US$ 747 million in 2032; it is expected to grow at a CAGR of 6.8% from 2026 to 2032.

In 2024, global Excipients for Effervescents production reached approximately 139.3 K tons, with an average global market price of around US$ 3,250 per tons.

Excipients for Effervescents are specialized functional auxiliary materials used in the production of effervescent tablets, mainly including acid sources (citric acid, tartaric acid), alkali sources (sodium bicarbonate, potassium bicarbonate), binders, disintegrants, and flavoring agents. They are compliant with pharmaceutical or food-grade standards, and their core function is to trigger rapid effervescence (releasing CO₂) when the tablet meets water, while also improving the tablet’s formability, stability, and taste. Non-toxic, moisture-resistant, and compatible with active ingredients, these excipients are critical to the efficacy, shelf life, and user experience of effervescent products in the pharmaceutical, health supplement, and food industries.

The single-line production capacity of Excipients for Effervescents is 5.6 to 5.9 K tons per year, the average gross profit margin was 38.8%.

The cost structure of Excipients for Effervescents is dominated by four core components with clear weights: raw material costs account for the largest share at 50%-60%, mainly high-purity food/pharmaceutical-grade acids, alkalis, and natural flavorings, where fluctuations in commodity prices (e.g., citric acid, sodium bicarbonate) directly drive overall cost volatility. Production and processing costs make up 20%-25%, covering purification, granulation, drying, and precision blending—strict control over particle size uniformity, moisture content, and purity (to meet GMP standards) increases manufacturing complexity. R&D and certification costs represent 10%-15%, dedicated to optimizing formulations (reducing effervescence noise, enhancing stability), developing low-sugar/low-sodium variants, and obtaining pharmaceutical/food safety certifications, as compliance and performance are core market barriers. Packaging and logistics costs constitute the remaining 5%-8%, including moisture-proof sealed packaging (to prevent hygroscopicity) and temperature-controlled transportation, with storage requiring dry, cool conditions to maintain product functionality.

The industry chain of Excipients for Effervescents consists of three interconnected tiers: upstream includes suppliers of basic chemical raw materials (citric acid, sodium bicarbonate), natural extracts (flavorings), and production equipment (granulators, blending machines), as well as providers of testing instruments and GMP certification services. Midstream involves enterprises engaged in raw material purification, formula compounding, processing, and quality inspection, focusing on adjusting component ratios and physical properties to match the production requirements of different effervescent products (pharmaceuticals, vitamins, beverage tablets). Downstream covers pharmaceutical companies, health supplement manufacturers, and food enterprises, with demand driven by the production of effervescent tablets, powders, and other effervescent formulations.

Demand for Excipients for Effervescents is growing steadily driven by the global popularity of effervescent products (valued for convenience, rapid absorption, and palatability), the expansion of the pharmaceutical and nutraceutical markets, and increasing consumer demand for low-sugar, natural, and functional formulations. It addresses pain points such as poor effervescence efficiency, short shelf life, and unpleasant taste of traditional excipients, while stricter safety and environmental standards further raise industry entry barriers. Key business opportunities lie in developing pharmaceutical-grade high-purity excipients for prescription drugs, formulating natural/organic variants for health supplements, and expanding into emerging markets with growing consumer health awareness (e.g., Southeast Asia, Latin America). Additionally, optimizing production processes to reduce costs and collaborating with downstream manufacturers for customized formulations can further tap into the high-growth potential of the effervescent auxiliary materials market.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Excipients for Effervescents market?

What factors are driving Excipients for Effervescents market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Excipients for Effervescents market opportunities vary by end market size?

How does Excipients for Effervescents break out by Functional Role, by Application?

This report presents a comprehensive overview of the global Excipients for Effervescents market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Functional Role

  • Acid Components
  • Carbonate And Bicarbonate Components
  • Fillers And Diluents
  • Binders And Disintegrants
  • Lubricants And Glidants
  • Sweeteners And Flavors

Segment by Physical Form

  • Powders
  • Granules
  • Co-Processed Systems
  • Direct-Compression Grades

Segment by Chemistry

  • Organic Acids And Salts
  • Inorganic Carbonates And Bicarbonates
  • Polyols And Sugars
  • Cellulosic And Polymer Excipients

Segment by Application

  • Pharmaceutical Products
  • Nutraceutical And Dietary Supplements
  • Food And Beverage Tablets
  • Veterinary Health Products

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Excipients for Effervescents market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Pharmaceutical Products, Nutraceutical And Dietary Supplements, Food And Beverage Tablets evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Excipients for Effervescents Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$474
2025
Forecast
$751.2
2032
CAGR
6.8%
2025–2032
Gebieden
5
global
Key companies
RoquetteSPI PharmaCD FormulationGattefosseBENEOJRS PharmaSyensqolehvoss Pharma
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Acid ComponentsCarbonate And Bicarbonate ComponentsFillers And DiluentsBinders And DisintegrantsLubricants And GlidantsSweeteners And Flavors
By Application
Pharmaceutical ProductsNutraceutical And Dietary SupplementsFood And Beverage TabletsVeterinary Health Products

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Acid Components
  • 3.1.3 Carbonate And Bicarbonate Components
  • 3.1.4 Fillers And Diluents
  • 3.1.5 Binders And Disintegrants
  • 3.1.6 Lubricants And Glidants
  • 3.1.7 Sweeteners And Flavors
  • 3.1.8 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Pharmaceutical Products
  • 4.1.3 Nutraceutical And Dietary Supplements
  • 4.1.4 Food And Beverage Tablets
  • 4.1.5 Veterinary Health Products
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Roquette
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 SPI Pharma
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 CD Formulation
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Gattefosse
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 BENEO
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 JRS Pharma
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Syensqo
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 lehvoss Pharma
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Merck
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Ashland
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Shin-Etsu
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 chasesun
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 HUNAN ER-KANG PHARMACEUTICAL
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 BASF Pharma Solutions
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Jungbunzlauer
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Solvay
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Arm & Hammer Performance Products
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Humens
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Dr. Paul Lohmann
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Excipients for Effervescents market?
The global Excipients for Effervescents market is estimated at US$ 474 million in 2025 (base year) and is projected to reach US$ 747 million by 2032.
How fast is the Excipients for Effervescents market expected to grow?
The market is expected to grow at a CAGR of 6.8% from 2026 to 2032, expanding from US$ 474 million in 2025 to US$ 747 million in 2032, roughly 1.6 times its base-year value.
What does the Excipients for Effervescents market cover?
In 2024, global Excipients for Effervescents production reached approximately 139.3 K tons, with an average global market price of around US$ 3,250 per tons.
What are the main segments of the Excipients for Effervescents market by functional role?
By functional role, the market is segmented into Acid Components, Carbonate And Bicarbonate Components, Fillers And Diluents, Binders And Disintegrants, Lubricants And Glidants and Sweeteners And Flavors.
Which applications drive demand in the Excipients for Effervescents market?
Key applications covered include Pharmaceutical Products, Nutraceutical And Dietary Supplements, Food And Beverage Tablets and Veterinary Health Products.
Who are the key players in the Excipients for Effervescents market?
Key players profiled include Roquette, SPI Pharma, CD Formulation, Gattefosse, BENEO, JRS Pharma, Syensqo and lehvoss Pharma, among 20 companies covered in total.
Which regions and countries are covered for Excipients for Effervescents?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Excipients for Effervescents market?
Downstream covers pharmaceutical companies, health supplement manufacturers, and food enterprises, with demand driven by the production of effervescent tablets, powders, and other effervescent formulations.
What challenges does the Excipients for Effervescents market face?
The cost structure of Excipients for Effervescents is dominated by four core components with clear weights: raw material costs account for the largest share at 50%-60%, mainly high-purity food/pharmaceutical-grade acids, alkalis, and natural flavorings, where fluctuations in commodity prices (e.g., citric acid, sodium bicarbonate) directly drive overall cost volatility.
Who should buy the Excipients for Effervescents market report?
The report is intended for manufacturers and solution providers, distributors and end users in Pharmaceutical Products, Nutraceutical And Dietary Supplements and Food And Beverage Tablets, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Excipients for Effervescents market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.